Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 12

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 12
---
 make payments in U.S. dollars if AMS Europe is unable to obtain euro” and “Description of the Notes — Issuance in Euro” in this prospectus supplement.

#### Additional Amounts
AMS Europe (or the guarantor, as the case may be) will, subject to certain exceptions and limitations, pay additional amounts as are necessary in order that the net payment of the principal of, premium, if any, and interest in respect of the notes, after any required withholding or deduction for any present or future tax, duty, assessment or other governmental charge imposed by a Relevant Taxing Jurisdiction (as defined below), will result in receipt by each holder of a note of such amounts as would have been received if no such withholding or deduction had been required. See “Description of the Notes — Additional Amounts” in this prospectus supplement.

#### Redemption for Tax Reasons
AMS Europe may redeem the notes of any series at any time, in whole but not in part, at its election in the event of certain changes in the tax laws of a Relevant Taxing Jurisdiction (as defined below) that would require AMS Europe, or certain acts taken by a taxing authority of a Relevant Taxing Jurisdiction that result in the substantial probability that AMS Europe would be required, to pay additional amounts with respect to the notes of such series as described under “Description of the Notes — Additional Amounts.” See “Description of the Notes — Redemption for Tax Reasons” in this prospectus supplement.

#### Ranking
Each series of the notes and the related guarantees will:

•

be senior unsecured obligations of AMS Europe and Boston Scientific, respectively;

•

rank equally in right of payment with any other existing and future senior unsecured and unsubordinated indebtedness of AMS Europe and Boston Scientific, respectively;

•

be senior to any future indebtedness of AMS Europe and Boston Scientific, respectively, that is subordinated to the notes and the related guarantees, as applicable;

•

be effectively junior to any future secured indebtedness of AMS Europe and Boston Scientific, respectively, to the extent of the collateral securing such indebtedness; and

<div align='center'>S-3</div>

TABLE OF CONTENTS

•

be structurally junior to any existing and future indebtedness and other liabilities of Boston Scientific’s subsidiaries (other than AMS Europe).

At December 31, 2024, we had outstanding approximately $10,746 million of unsecured indebtedness and no secured indebtedness. In addition, certain of our subsidiaries had approximately $175 million of outstanding indebtedness at December